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Abstract
Background: Many opiate users entering British prisons require prescribed medication to help them achieve
abstinence. This commonly takes the form of a detoxification regime. Previously, a range of detoxification agents
have been prescribed without a clear evidence base to recommend a drug of choice. There are few trials and very
few in the prison setting. This study compares dihydrocodeine with buprenorphine.
Methods: Open label, pragmatic, randomised controlled trial in a large remand prison in the North of England.
Ninety adult male prisoners requesting an opiate detoxification were randomised to receive either daily sublingual
buprenorphine or daily oral dihydrocodeine, given in the context of routine care. All participants gave written,
informed consent. Reducing regimens were within a standard regimen of not more than 20 days and were at the
discretion of the prescribing doctor. Primary outcome was abstinence from illicit opiates as indicated by a urine
test at five days post detoxification. Secondary outcomes were collected during the detoxification period and then
at one, three and six months post detoxification. Analysis was undertaken using relative risk tests for categorical
data and unpaired t-tests for continuous data.
Results: 64% of those approached took part in the study. 63 men (70%) gave a urine sample at five days post
detoxification. At the completion of detoxification, by intention to treat analysis, a higher proportion of people
allocated to buprenorphine provided a urine sample negative for opiates (abstinent) compared with those who
received dihydrocodeine (57% vs 35%, RR 1.61 CI 1.02–2.56). At the 1, 3 and 6 month follow-up points, there
were no significant differences for urine samples negative for opiates between the two groups. Follow up rates
were low for those participants who had subsequently been released into the community.
Conclusion: These findings would suggest that dihydrocodeine should not be routinely used for detoxification
from opiates in the prison setting. The high relapse rate amongst those achieving abstinence would suggest the
need for an increased emphasis upon opiate maintenance programmes in the prison setting.
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Background
Prison populations include a high proportion of people
who use illicit substances and are dependent upon illicit
opiates [1]. Levels of drug use among prisoners tend to be
much higher than in the general population [2]. In the
United Kingdom (UK) almost two thirds of injecting drug
users have spent some time in prison [3] and repeat drug-
related offending and re-incarceration is common [3].
Illicit opiate users who enter the prison estate in the UK
are typically offered pharmacological interventions of
opiate maintenance treatment, or an opiate detoxification
regime complimented by psychosocial support according
to individual health need [4].
Historically, healthcare provision for injecting drug users
in prisons in England and Wales has not been equivalent
to that offered in community settings. There has recently
been a phased re-organisation in prison healthcare with
responsibility in England and Wales being transferred
from the Home Office to individual National Health Serv-
ice (NHS) Primary Care Trusts (PCT) [5]. Alongside this,
current developments in drug policy have been designed
to facilitate a change in prison based clinical practice to
enable it to become equivalent to that offered in the com-
munity [6-9]. In support of this policy directive, financial
resource is being provided to prisons to supply an inte-
grated system for drug maintenance or detoxification
treatment within nationally agreed clinical guidelines [4].
Consequently, all prisoners whose urine tests are positive
for illicit opiates should be offered an opiate detoxifica-
tion of equivalent standard to that in the community.
As many drug users reduce or cease illicit drug use whilst
in prison, providing treatment for opiate detoxification is
a core function of prison healthcare provision [4]. How-
ever, during the period when the current research was con-
ducted (2004/2005) the evidence base and the national
guidelines on the clinical management of drug misuse
[10] did not stipulate a 'drug of choice' for opiate detoxi-
fication. In the absence of this evidence base, a wide vari-
ety of agents for opiate detoxification have previously
been prescribed at the discretion of prison clinicians. Such
medications include methadone, dihydrocodeine,
buprenorphine, lofexidine and clonidine. Historically
within UK prisons, the most commonly used drug for opi-
ate detoxification has been dihydrocodeine. Anecdotally
this was partly due to a reluctance to prescribe methadone
following a small number of methadone related deaths in
the prison setting. Dihydrocodeine has been attractive to
clinicians as it has a shorter half-life than methadone, and
seems equally acceptable to users. Robertson et al (2006)
found that there was no significant difference in retention
in treatment between dihydrocodeine and methadone for
maintenance treatment in the community [11]. Towards
the end of the study period (late 2005), there was a
national move away from prescribing dihydrocodeine in
the British prison setting due to its potential for diversion
by prisoners into the shadow economy.
Buprenorphine, in the form of sub-lingual tablets, has the
potential advantage of having a good safety profile, better
retention in treatment and lower withdrawal severity
when compared to methadone, lofexidine or clonidine
[12-16]. Comparatively, it has been increasingly pre-
scribed in the community for the purpose of opiate
detoxification [17]. The latest Department of Health
guidelines recommend either buprenorphine or metha-
done as first line agents for prisoners requesting an opiate
detoxification, subject to clinician discretion [4].
Recently, the results of the Leeds Evaluation of Efficacy of
Detoxification Study (LEEDS) were published [18]. The
study was a randomised controlled trial (RCT) comparing
buprenorphine and dihydrocodeine for opiate detoxifica-
tion in the community drug treatment setting and showed
that participants were more likely to achieve abstinence
from illicit opiates at completion of detoxification with
buprenorphine. However there are potentially differences
in the demographics, drug histories and structuring of
drug treatment in the community compared to the prison
which limits the external validity of these findings in the
prison treatment setting. Consequently, the research team
considered it imperative that the same detoxification
agents were compared within the prison estate. Addition-
ally, there appears to be a paucity of clinical trials con-
ducted worldwide in the prison setting which have
evaluated medication for opiate detoxification. Whilst
one British study evaluated the withdrawal severity of
methadone versus lofexidine, the rates of completion
were not sufficient to detect a statistically significant dif-
ference between the medications [19]. Given the dearth of
randomised controlled trials for opiate detoxification in
this environment, we felt it appropriate to introduce this
methodology to answer an important research question
which could inform clinical policy, decision making and
prison policy directives [20]. This paper reports the find-
ings of a trial comparing dihydrocodeine and buprenor-
phine for opiate detoxification in the UK prison setting.
Methods
Setting
Her Majesty's Prison Leeds. This is a large category B local
remand prison1 in the North of England, with over 1200
bed spaces. It accepts over 6000 adult male prisoners per
year, primarily from the West Yorkshire area.
Design
Pragmatic open label randomised controlled trial com-
paring two detoxification interventions – oral dihydroco-
deine and sublingual buprenorphine. RandomisationSubstance Abuse Treatment, Prevention, and Policy 2009, 4:1 http://www.substanceabusepolicy.com/content/4/1/1
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sequence, with random block size, was generated using
Microsoft Excel RAND function, by CEA in the Depart-
ment of Psychiatry at the University of Leeds. CEA pre-
pared sealed opaque consecutively numbered envelopes
concealing the name of the allocated intervention. CEA
had no contact with eligible participants.
The Multi Centre Research Ethics Committee for Wales
(MREC Wales) approved the study in May 2004, and the
Research Governance Organisation (Bradford South and
West PCT) in April 2004.
Eligibility
Inclusion criteria
1. Male (since research only took place in the male estate,
thereby implicitly excluding women)
2. 18 – 65 years
3. Using illicit opiates as confirmed by a urine test taken
at first assessment
4. Expressing a wish to detoxify through the standard
monitored process and remain abstinent from opiates
5. Willing to give informed consent after receiving the par-
ticipant information sheet
6. Remaining in custody in HMP Leeds for longer than 28
days
Exclusion criteria
1. Contraindications to dihydrocodeine or buprenor-
phine
2. Co-existing acute medical conditions requiring emer-
gency admission for hospital care so precluding detoxifi-
cation in the prison setting
3. Currently undergoing detoxification from other illicit
drugs whereby concurrent detoxification from opiates
would not be clinically indicated
4. Previous randomisation into the trial
Recruitment
Participants were recruited from the medical reception
area on arrival into HMP Leeds. On their first night in
HMP Leeds, those with a current history of illicit opiate
use (as confirmed by a Sure Screen multi panel drugs test)
are routinely offered a detoxification regime. When pris-
oners who fulfilled the inclusion criteria approached the
prison doctor, the purpose and rationale of the trial was
explained to them. If they provided informed consent, the
prison doctor (NW or HE) randomised them by opening
the next pre-prepared opaque envelope and prescribing
the intervention named within. Up to the point of open-
ing the envelope both prisoner and doctor were blind to
the intervention; once the envelope was open both pris-
oner and doctor knew the allocated intervention. On the
opening of the envelope, the prison nursing staff and the
prison pharmacist were informed of the allocated inter-
vention for each participant. Standard clinical care contin-
ued from this point onwards.
Randomisation took place between July 2004 and July
2005. Some prisoners may have chosen to enter the trial
as during this period, the standard detoxification choices
offered to prisoners were dihydrocodeine and buprenor-
phine. This was regardless of whether they entered the
trial or not, so it was only strong patient preference which
predominantly meant people declined to take part.
Recruitment was disappointing during the first five
months of the trial (See Table 1 for breakdown of the
actual rates of recruitment per month and also anticipated
recruitment). So, in September 2004 (following MREC
approval) the research team decided to provide an incen-
tive of £5 which was credited to the prisoners' phone
accounts (operated by a PIN number). The incentive was
credited upon entry to the trial and prisoners were aware
Table 1: Rates of recruitment per month versus anticipated 
recruitment
Actual recruitment Anticipated recruitment
Jul 2004 1 10
Aug 2004 2 10
Sep 2004 2 10
Oct 2004 2 10
Nov 2004 0 10
Dec 2004 7 10
Jan 2005 19 10
Feb 2005 17 10
Mar 2005 13 10
Apr 2005 4 10
May 2005 12 10
Jun 2005 3 10
Jul 2005 8 10Substance Abuse Treatment, Prevention, and Policy 2009, 4:1 http://www.substanceabusepolicy.com/content/4/1/1
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that they could withdraw at any time, yet keep the accred-
ited incentive. We felt this incentive was an appropriate
gratitude for prisoners to provide the voluntary urine sam-
ples and information that were required as part of taking
part in the study. After introduction of the incentive,
recruitment rates remained static but then increased in
December and fluctuated somewhat. Ideally, it would
have been beneficial to be able to provide incentives for
urine samples at the secondary outcome points in order to
increase the follow up rates.
Interventions
Dihydrocodeine was given openly in the context of the
standard prison doctor and drugs worker support. It was
prescribed as a 30 mg oral tablet preparation "in-posses-
sion" medication. The medication was administered once
a day to the participant who held the supply of medica-
tion to take in four daily divided doses.
Buprenorphine was given openly, in the context of the
standard prison doctor and drugs worker support. It was
dispensed either as 8 mg, 2 mg or 0.4 mg sublingual tablet
preparation under daily supervised consumption.
The reducing regimen of both medications was at the dis-
cretion of the prescribing doctor. However, in practice, the
detoxification regimes were subject to a protocol so as to
fit into the high volume, busy nature of the prison regime.
The dose prescribed did not exceed the standard regimes
(Table 2). Therefore, the total dose administered was 96
mg of buprenorphine over 20 days and 6660 mg of dihy-
drocodeine over 20 days.
Sample size
As no randomised controlled trials relevant to these com-
parisons have been previously undertaken in the prison
setting, there was no comparable study on which to base
the sample size calculation. The only other controlled trial
comparing agents for detoxification (methadone and
lofexidine) in a UK prison randomised 74 prisoners [19].
However, the project team completed a detoxification
trial in the homeless community comparing dihydroco-
deine with buprenorphine [20]. From this, we estimated
that with a sample size of 60 we would have a finding of
clinical and statistical significance for differences in the
primary outcome. Due to loss of follow-up we determined
a sample size of 120 would have sufficient power (i.e
80%) to determine a difference in the secondary out-
comes between the two arms of 70% versus 45% [OR
1.56; α = 0.05 (two-sided)]. The power calculation was
undertaken using Sample Power 1.20 developed by SPSS
Inc., comparing two groups (60 individuals in each) and
for α = 0.05 (two-sided).
Data collection and Outcomes
The LEEDS trial co-ordinator (LS) collected details of allo-
cated detoxification agent, background history, demo-
graphic details and use of opiates from the participant's
prison medical records.
Primary outcome
Abstinence from illicit opiates at five days post detoxifica-
tion as indicated by a supervised Sure Screen multi panel
drugs test negative for opiates. This urine test was taken by
a prison nurse who was prompted by LS at the appropriate
follow-up time period.
Secondary outcomes
During the period of detoxification
Serious and Adverse Events – As part of routine clinical prac-
tice, clinicians and drugs workers noted any adverse
events by making an entry in the participant's medical
records. LS extracted data of adverse events clearly result-
ing in clinically significant distress to study participants or
of major concern to clinicians from medical records, for
the period of detoxification, and transcribed these onto a
database.
Leaving the study early – perceived reasons for withdrawal
were recorded.
Inappropriate use of prescribed medication – examples of this
included intentional overdose, storing, trading, swapping
or selling of prescribed medication.
Table 2: Detoxification regimens
Buprenorphine Dihydrocodeine
Day Dose (mg)
morning evening
1 6 2 × 120 2 × 120
2 8 2 × 120 2 × 120
3 8 2 × 120 2 × 120
4 8 2 × 120 2 × 120
5 8 2 × 120 2 × 120
6 8 2 × 120 2 × 120
7 8 2 × 120 2 × 120
8 8 1 × 120, 1 × 90 1 × 120, 1 × 90
9 6 1 × 120, 1 × 90 1 × 120, 1 × 90
10 6 2 × 90 2 × 90
11 4 2 × 90 2 × 90
12 3.6 1 × 90, 1 × 60 1 × 90, 1 × 60
13 3.2 1 × 90, 1 × 60 1 × 90, 1 × 60
14 2.8 2 × 60 2 × 60
15 2.4 2 × 60 2 × 60
16 2.0 1 × 60 2 × 60
17 1.6 1 × 60 2 × 60
18 1.2 1 × 60 1 × 60
19 0.8 1 × 60 1 × 60
20 0.4 XXXX 1 × 60Substance Abuse Treatment, Prevention, and Policy 2009, 4:1 http://www.substanceabusepolicy.com/content/4/1/1
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Service utilisation – admission to hospital, Accident and
Emergency and in-patient stays in prison hospital health-
care wing were recorded.
At 1, 3, and 6 months post detoxification
Abstinence status – if the prisoner was still in HMP Leed-
sthese data were extracted from clinical notes. If the per-
son had been transferred, other prisons were contacted. If
the prisoner had been released into the community, evi-
dence of abstinence status was primarily ascertained
through local community drugs service or GPs records.
There was some, albeit limited, success tracing people via
the address or telephone number which they had pro-
vided at the point of randomisation.
Service utilisation (as above)
All data was recorded on a Microsoft Excel spreadsheet.
Significant loss to follow-up occurred due to the high
turnover of prisoners in HMP Leeds. Being a busy remand
prison, the eligibility criteria of "remaining in custody in
HMP Leeds for longer than 28 days" was determined so
that the primary outcome would be complete for most
participants. At the point of randomisation, remand pris-
oners who were due to appear in court in less than 28 days
time were asked the likelihood of returning to HMP Leeds
and invited to take part accordingly.
Analysis
Following data entry, all analyses were undertaken using
Review Manager 4.2.8 and SPSS software. The analysis of
the primary outcomes was by a simple 2 × 2 table.
Dummy tables were constructed for all secondary out-
comes. These tables were designed as rigid templates for
the final write up of the research, and to facilitate the
researchers to collate a full data set and to mitigate against
data dredging. Primary outcomes were analysed on an
intention-to-treat basis: if the person did not finish the
course of detoxification or did not give a urine sample
then this was considered as a positive urine test for opi-
ates. Intention-to-treat was used as a replication of the
analysis performed in the trial conducted in the commu-
nity [18] rather than other methods e.g. multiple imputa-
tion. Primary outcomes at follow-up were analysed both
as per protocol (excluding those lost to follow-up) and
intention-to-treat (missing urines assumed positive) with
relative risk tests for categorical data and unpaired t-tests
for continuous data. Secondary outcome data were ana-
lysed using chi square tests.
Results
Participants
Ninety men, that is 64% of those who were eligible and
approached to take part in the study, consented to recruit-
ment (Figure 1). These men were imprisoned in HMP
Leeds and using illicit opiates prior to their sentence. The
average age was 29.8 years (range 19–53) with the mean
age for those allocated buprenorphine being 28.9 (SD
4.6) and 29.7 for those allocated dihydrocodeine (SD
6.1). The duration of using opiates overall was 9.3 years
(range 1–18) with a mean of 8.9 years for those allocated
buprenorphine (SD 3.5) and 9.7 years for those allocated
dihydrocodeine (SD 4.6). Forty two men were randomly
allocated to buprenorphine and 48 to dihydrocodeine.
Variables relating to age, pattern of use and prognosis
were evenly distributed between groups (Table 3).
Table 3: Demographic characteristics and prognostic factors
Buprenorphine
(n = 42)
Dihydrocodeine
(n = 48)
Age – mean (SD) 28.9 (4.6) 29.7 (6.1)
Pattern of use
How are opiates taken?
IV 21 (50%) 18
Smoking 9 12
Methadone maintenance 2 0
Don't know 10 18
Current daily use
minimum – mean (SD) £40.00 (21.10) £42.10 (29.40)
maximum £45.48 (23.39) £45.65 (30.21)
Duration taking opiates – mean (SD) 8.9 (3.5) years 9.70 (4.6) years
Initial urine
illicit opiates present 28/30 27/27
other drugs present 16/30 13/27
Prognostic factors
Yes No D/K Yes No D/K
Previous detoxes? 27 3 4 25 4 3
Successful detoxes? 11 9 10 13 8 6Substance Abuse Treatment, Prevention, and Policy 2009, 4:1 http://www.substanceabusepolicy.com/content/4/1/1
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Flow chart of randomisation outcome Figure 1
Flow chart of randomisation outcome.
Allocated and received 
dihydrocodeine (n=48) 
Allocated and received 
buprenorphine (n=42) 
Provided final 
urine sample 
positive for illicit 
opiates (n=8)
Released (n=8)
Transferred to 
another prison 
(n=0)
Detox not 
completed for any 
other reason (n=2) 
Randomised (n=90) 
Unsuccessful 
detoxification 
Unsuccessful 
detoxification 
Provided final 
urine sample 
positive for illicit 
opiates (n = 14)
Released (n=10)
Transferred to 
another prison 
(n=4)
Detox not 
completed for any 
other reason (n=3)
Successful 
detoxification – final 
urine sample free 
from illicit opiates 
(n=24)
Successful 
detoxification – final 
urine sample free 
from illicit opiates 
(n=17)
Eligible and approached 
(n=140)
Refused (n=50) Substance Abuse Treatment, Prevention, and Policy 2009, 4:1 http://www.substanceabusepolicy.com/content/4/1/1
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Primary outcome
Overall, 63 men (70%) gave a urine sample at 5 days post
detoxification (Table 4), between the two allocated regi-
mens for provision of urine sample (RR 1.18, CI 0.90 –
1.54, z = 1.20, p = 0.43). 27 men (30%) did not provide a
urine sample. 18 were released before their urine sample
was due, 4 were transferred to another prison and 5 did
not complete the prescribed detoxification regime. Of
those released or transferred, 11 did not complete the
detoxification, 4 completed the regime but left HMP
Leeds before their urine test was due and 5 left on the day
of the test or afterwards (data unavailable for 2). There
Table 4: Results
Buprenorphine
(total = 42)
Dihydrocodeine
(total = 48)
Relative Risk
(95% CI)
Unpaired t-test P value
By end of detox
Final urine sample 32/42 31/48 1.18 (0.90, 1.54) N/A 0.43
Per protocol negative urine 24/32 17/31 1.37 (0.94, 1.99) N/A 0.10
ITT negative urine 24/42 17/48 1.61 (1.02, 2.56) N/A 0.04
Leaving early 10/42 15/48 0.76 (0.38, 1.51) N/A 0.43
Overdose 00 N / A
Inappropriate use of allocated drug 3/29 1/25 2.59 (0.29,23.32) N/A 0.39
A&E attendance 0 0 N/A
Hospital admittance 0 0 N/A
Prison doctor visits (mean) 1.0 (0.5) n = 28 1.0 (0.6) n = 23 N/A t(49) = 0.00 1.00
At 1 months post detoxification
Dead 0/33 0/33 N/A
Abstinent (ITT) 16/42 17/48 1.08 (0.63, 1.85) N/A 0.79
How known?
Urine test 4/10 2/5 1.00 (0.27, 3.72) N/A
Self report 12/21 15/25 0.95 (0.58, 1.55) N/A 1.00
A&E attendance 0/33 0/33 N/A 0.84
Hospital attendance 0/33 0/33 N/A
Prison doctor visits (mean) 0.4 (0.9) n = 25 0.6 (1.0) n = 28 N/A t(51) = 0.76 0.45
Drug worker visits
(mean)
0.2 (0.4) n = 3 2 n = 1 N/A
At 3 months post detoxification
Dead 0/27 0/23 N/A
Abstinent (ITT) 13/42 12/48 1.24 (0.64, 2.41 N/A 0.53
How known?
Urine test 2/8 1/4 1.00 (0.13, 8.00) N/A 1.00
Self report 11/18 11/18 1.00 (0.59, 1.68) N/A 1.00
A&E attendance 1/27 1/23 0.85 (0.06,12.87) N/A 0.91
Hospital attendance 2/27 1/23 1.70 (0.16,17.60) N/A 0.65
Prison doctor visits (mean) 0.8 (1.7) n = 17 1.5 (1.9) n = 17 N/A t(32) = 0.76 0.27
Drug worker visits (mean) 0 No data N/A
At 6 months post detoxification
Dead 0/14 0/12
Abstinent 5/42 5/48 1.14 (0.36, 3.68) N/A 0.82
How known?
Urine test 1/3 1/4 1.33(0.13,13.74) N/A 0.81
Self report 4/11 4/8 0.73 (0.26, 2.07) N/A 0.55
A&E attendance 2/14 1/12 1.71(0.18,16.65) N/A 0.64
Hospital attendance 3/14 2/12 1.29 (0.26, 6.46) N/A 0.76
Prison doctor visits (mean) 2.0 (2.2) n = 4 2.2 (1.5) n = 4 N/A
Drug worker visits (mean) No data N/A
*ITT assumption = everybody not returning for final urine test had positive urine
* Statistical tests were z (approximation) testsSubstance Abuse Treatment, Prevention, and Policy 2009, 4:1 http://www.substanceabusepolicy.com/content/4/1/1
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was no statistically significant difference in demographic
variables at baseline between those who completed
detoxification and those who did not.
At the completion of detoxification, by intention to treat
analysis, we found a higher proportion of people allo-
cated to buprenorphine provided a urine sample negative
for opiates (abstinent) compared with those who received
dihydrocodeine (57% vs 35%, RR 1.61 CI 1.02–2.56, z =
2.065, p = 0.04).
Secondary outcomes
At one month, follow up data were obtained on 66 partic-
ipants (73% of the study sample). At three months, follow
up data were obtained on 55 participants (61% of the
study population). At six months, follow up data were
obtained on 26 participants (29% of the study popula-
tion).
At the 1, 3 and 6 month follow-up points, there were no
statistically significant differences for urine samples nega-
tive for opiates between the two groups. There were also
no statistically significant differences for any other of the
secondary outcomes of Accident and Emergency attend-
ance, hospital attendance, GP visits or drugs worker visits
throughout this post-treatment period (Table 4). No seri-
ous adverse events were reported throughout the study.
Discussion
The findings
Our study showed that at five days after completion of the
prison detoxification regime, buprenorphine at a total
dose of 96 mg was more effective than dihydrocodeine at
a total dose of 6660 mg in achieving abstinence from
illicit opiates. It also showed that 43% of HMP Leeds' pris-
oners with a habit of illicit opiate use, who agreed to be
included in the study, continued to acquire and use opi-
ates even through the first few days of imprisonment and
prescribed detoxification regimen.
It is possible that the research was underpowered to deter-
mine the effect of the interventions upon longer term
abstinence, as at the secondary follow up points there
were no statistically significant differences between the
two groups for urine samples negative for opiates. How-
ever, it may be that there was clinically no significant dif-
ference. To this effect, firm conclusions regarding the
effectiveness of buprenorphine and dihydrocodeine
detoxification on post release opioid use and other core
outcomes can not be conclusively determined. It is well
known that post release from prison is a high risk time for
relapse into illicit drug use. Therefore, it could be that
more meaningful follow up data from prison based
detoxification trials could be derived based on the time
since release from prison in addition to time since detoxi-
fication.
A direct comparison can be made between the results of
this study and those of the sister trial conducted in the
community [18]. As previously stated, the result of the
community trial also favoured buprenorphine over dihy-
drocodeine for opiate detoxification. Most importantly,
completion of detoxification and provision of final urine
in the prison environment was much higher than in the
community (23% vs 70%). Reasons for this are varied but
may include inherent characteristics of the treatment set-
ting. For the participants who remained in HMP Leeds,
when their urine sample was due, the closed, secure envi-
ronment meant they were actively traced by prison nurses
who took the urine samples. This contrasts with the very
different environment of the community where the
research team were dependent on the participants return-
ing to their general practice to collect their final prescrip-
tion so that a urine sample could be taken.
It is important to state that the trial did not introduce any
new intervention medications into HMP Leeds as dihy-
drocodeine and buprenorphine were the only detoxifica-
tion agents available during the period of randomisation
[20]. The trial took place for a year from summer 2004,
which is important as during this period the first line
agent for most UK prisons was dihydrocodeine, with
buprenorphine slowly being introduced. It seemed perti-
nent to compare these two agents, given that they were
being prescribed to thousands of prisoners with a history
of illicit opiate use every year in UK prisons despite no
previous evaluation of their clinical effectiveness. Current
policy recommendations are very different, with metha-
done and buprenorphine now being advocated as first
line agents for opiate detoxification [4]. However, anecdo-
tally, a practice of dihydrocodeine prescribing continues
in many UK prisons.
Whilst there is a paucity of opiate detoxification trials con-
ducted with prisoners, some studies have highlighted pris-
oners' subjective experiences of opiate detoxification. One
recent qualitative study identified that prisoners in Eng-
land who had been prescribed dihydrocodeine found that
it was often inadequate at relieving acute opiate with-
drawal and they were often reduced too quickly [21].
More favourable prison detoxification experiences were
noted with buprenorphine and methadone [21]. Other
studies have reported prisoners' sense of inadequacy in
relation to short term methadone detoxifications [22,23]
where the length of the detoxification is perceived as too
short. Length of detoxification has now increased in UK
prisons [4] and methadone and buprenorphine have
become first line agents in the prison estate [4].Substance Abuse Treatment, Prevention, and Policy 2009, 4:1 http://www.substanceabusepolicy.com/content/4/1/1
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Current UK guidelines regarding the treatment of drug
misuse in prisons recommend that only licensed opiate
agonist medications (such as methadone or buprenor-
phine) should be used in the pharmacological treatment
of opiate detoxification [4]. This recommendation was
based on face validity consensus view of experts working
in the field. Our findings strengthen and provide empiri-
cal support for the current guidelines which do not recom-
mend the routine use of dihydrocodeine as a first line
agent for detoxification in the prison setting. Outside of
prison, recent clinical guidance from UK's National Insti-
tute of Clinical Excellence [24] has recommended against
the routine use of dihydrocodeine for opiate detoxifica-
tion based on evidence from the LEEDS trial in the com-
munity [18] and unpublished data from this current
study. Both suggested no advantage in effectiveness of
dihydrocodeine over buprenorphine either in the com-
munity or the prison.
Methodological issues
LEEDS is only one of a small number of randomised con-
trolled trials to take place in the UK prison estate. [25] The
research team encountered barriers when conducting the
community trial [18] such as patient preference, clinical
equipoise and logistical issues [26]. Patient preference was
a difficulty that carried through to the prison setting and
was probably the largest hurdle to randomising people
into the trial. However, conducting this trial in the prison
environment presented many new problems and issues.
Most significantly, the research team had to be satisfied
that all prisoners gave informed consent and that they
understood the processes of the trial. This was sometimes
difficult in the noisy and chaotic environment of first
night medical reception. Additionally, the reception area
has a fast throughput and was not often conducive to the
intricacies of a research trial. On some occasions, poten-
tial participants were not randomised if it was thought
that they did not fully understand the concept of the trial
or – more often – the process of randomisation. This was
usually the case when they were in physical withdrawal
from illicit opiates.
One weakness of the study was not recording demo-
graphic details of those who declined to participate as we
cannot compare this group with those who agreed to be
involved. Also this study involved men over the age of 18.
Therefore applicability of the findings to women and
young people in prison is problematic. Additionally, there
are limitations with the intention-to-treat analysis used as
this assumes that all missing urines tests are positive for
opiates. Whilst we acknowledge this is problematic, this
trial was analysed according to statistical convention in
the UK and in keeping with the analysis of the sister trial
previously conducted in the community.
Data collection was difficult when prisoners were trans-
ferred to serve their remaining sentence at other establish-
ments across the wider prison estate. Indeed, there was a
wide variation of responses to requests for help obtaining
important information from other prison healthcare
departments, despite having the necessary ethical and
governance approvals in place to facilitate this. Whilst
some prison healthcare departments at other establish-
ments were willing to share information for the purposes
of the trial, despite our best efforts, others refused. This
sometimes led to a loss of follow up data from prisoners
who were participating in the trial who had been trans-
ferred to certain unhelpful establishments.
As far as the research team are aware, this study is the only
opiate detoxification randomised controlled trial in a
prison setting which has taken abstinence from opiates
(as indicated by a urine test) as the primary outcome. For
studies assessing efficacy of opiate detoxification agents,
an accurate and independent measure of abstinence status
is important Cf [27]. The only other prison trial with
which to compare is Howells et al (2002) [19]. In this UK
study of 74 male prisoners with opiate addiction, lofexi-
dine was compared with methadone with the primary
outcome being self-reported withdrawal symptom sever-
ity during the detoxification period. Variously, other trials
comparing agents for opiate detoxification in a variety of
settings have used intensity/symptoms of withdrawal,
retention in treatment, completion of treatment, nature of
adverse effects [16,28] and relapse rate [28]. We believe
that our first line method of ascertaining abstinence status
via a urine test represents the most robust and binary
manner in which to answer a clinical research question
pertaining to the efficacy of detoxification medications.
We undertook this study on a minimal budget (one half
time research assistant post for co-ordination and data
collection over 19 months). Prison doctors (NW and HE)
randomised in addition to their everyday clinical roles
and responsibilities (approximately 5 to 8 minutes per
participant). The research team believed this trial is imper-
ative in order to ascertain whether a randomised control-
led trial with drug using prisoners, which recorded
abstinence, was feasible in UK prisons. The high through-
put of large numbers of prisoners in an environment that
is recognised as a high risk for overdose, self-harm and
suicide [29] certainly presents significant logistical barri-
ers to the smooth running of a research project. However,
we do acknowledge that the very low follow up rate of this
study is problematic and it may be pertinent for future
studies to examine more rigorously whether buprenor-
phine was superior to dihydrocodeine at post release.Substance Abuse Treatment, Prevention, and Policy 2009, 4:1 http://www.substanceabusepolicy.com/content/4/1/1
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Future research
This study raises further research questions. Since comple-
tion of this trial, the issue of buprenorphine abuse in the
UK prison estate has been highlighted [30]. Therefore it
could be that whilst our findings would suggest that dihy-
drocodeine should not routinely be used for detoxifica-
tion in the prison setting, there could be other more
effective agents than buprenorphine. In particular it is
possible that methadone mixture is the pharmacological
agent that is both most clinically effective and least ame-
nable to diversion in the prison setting. Currently the
Department of Health is supporting the research team to
undertake a multi-prison trial comparing methadone with
buprenorphine regimens for opiate detoxification. After a
lengthy period completing the necessary approvals [31],
recruitment for this trial began in January 2006. Randomi-
sation and data collection for this research is currently
ongoing, with almost 300 prisoners recruited to date
across three prisons in the North of England. Methadone
and buprenorphine are now the two first line detoxifica-
tion medications within the British prison estate and a
comparison is therefore fundamental to inform the cur-
rent knowledge and evidence base.
The research team believe that conducting qualitative
work around this trial may strengthen and give depth to
the findings, particularly in relation to those people who
were not abstinent at the primary outcome stage. It would
have been interesting to understand how prisoners viewed
the experience of their detoxification and how issues
peculiar to the nature of prison life and drug use were
worked out and overcome. Consequently, we would rec-
ommend that future randomised controlled trials (in a
variety of settings) incorporate a qualitative element into
their design in order to understand the holistic experience
of simultaneously being a patient and research partici-
pant.
Conclusion
This study suggests that buprenorphine may be more
effective than dihydrocodeine for adult men undergoing
opiate detoxification in the prison environment. How-
ever, it also demonstrates the high level of illicit opiate use
within the prison estate even for those entered into a
detoxification programme, with over 40% of prisoners in
this study showing evidence of illicit opiates in their urine.
The results of this trial reinforce current guidelines which
do not recommend dihydrocodeine is prescribed as a first
line agent for the management of opiate misuse. The high
rate of relapse into opiate use post-intervention would
also suggest a greater role for opiate maintenance in the
prison estate as abstinence is not a realistic goal for many
drug users within this environment. There is an emerging
evidence base for the effectiveness of opiate maintenance
programmes in the prison setting [32].
The research team encountered novel methodological
issues and problems when randomising in the prison
environment, the most crucial being informed consent.
Data collection was also problematic once prisoners had
been released or transferred to other establishments. In
outlining our research experience, we hope to inform
other research teams of the logistical issues of conducting
a clinical trial in the British prison estate. Most signifi-
cantly, this research demonstrates that a pragmatic ran-
domised controlled trial can  be undertaken in this
difficult and challenging environment.
Notes
1. Category B refers to a prison which is high but not max-
imum security. HMP Leeds is classed as a local prison in
that it predominantly accepts men from the local area
which is the county of West Yorkshire.
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